Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.
Atomo Diagnostics Limited has successfully completed a Shortfall Placement, raising $416,611.77 from institutional and sophisticated investors. This follows a recent order from Lumos Diagnostics for Atomo’s Pascal cassettes to support the increased demand for FebriDx® in the US market. The funds raised will support Atomo’s working capital and ongoing business objectives, positioning the company strongly for future operational activities.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that provides unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The company’s patented devices enhance usability and reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized several products internationally, focusing on infectious diseases such as HIV, Active Syphilis, and viral vs bacterial differentiation, as well as early pregnancy detection.
Average Trading Volume: 1,301,386
Technical Sentiment Signal: Hold
Current Market Cap: A$15.75M
See more data about AT1 stock on TipRanks’ Stock Analysis page.